2 active trials 1 recruiting 1 Phase 3 2 disease areas
| Phase 3 | 1 | |
| Phase 4 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06113913 | Subcutaneous Infliximab After A Previous Intravenous Dose Optimization | Inflammatory Bowel Diseases | Recruiting | 2024-07-26 |
| Phase 3 | ||||
| NCT05299931 | An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients… | Crohn Disease | Active, Not Recruiting | 2025-02-05 |
Crohn's Disease (2) · Ulcerative Colitis (1)